Thermo Fisher Scientific (TMO) Receivables - Other (2018 - 2026)

Thermo Fisher Scientific (TMO) has reported Receivables - Other for 9 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.7 billion, up 23.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 23.28% YoY), and the FY2025 annual result was $1.7 billion, up 16.1% from the prior year.
• Receivables - Other was $1.7 billion for Q1 2026 at Thermo Fisher Scientific, up from $1.7 billion in the prior quarter.
• Over five years, Receivables - Other peaked at $1.7 billion in Q1 2026 and troughed at $1.1 billion in Q2 2022.
• Average Receivables - Other over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2025.
• Year-over-year, Receivables - Other surged 54.46% in 2022 and dropped 3.94% in 2025.
• Over 5 years, Receivables - Other stood at $1.3 billion in 2022, then increased by 9.98% to $1.4 billion in 2023, then slipped by 0.55% to $1.4 billion in 2024, then grew by 16.1% to $1.7 billion in 2025, then increased by 1.08% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.